Humanized antibodies against CD3
US7381803B1 · kind B1 · utility
35Cited by
17References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 18, 2000 |
| Grant date | Jun 3, 2008 |
| Priority date | — |
| Expiry date | Jul 18, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides bispecific antibodies with selective cytotoxicity against malignant B-cells. The bispecific antibodies bind to an effector cell antigen and to a 28/32 kDa heterodimeric protein on the surface of malignant B-cells. The invention also includes the monospecific components of the bispecific antibodies, humanized versions thereof, and humanized bispecific antibodies. The invention further provides therapeutic and diagnostic methods employing these antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.